Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab PK/Safety in Healthy Chinese Volunteers
NCT03380780Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2018
- Primary completion
- Sep 2018
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Roche. Primary endpoints: Maximum Observed Plasma Concentration at Day 113 and Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity at Day 113. Started Mar 2018; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03380780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380780.